Product Overview

Vomistop Tablet is a prescription medication formulated to manage acute and chronic nausea and vomiting. Manufactured by Cipla Limited, each strip contains ten dissolvable tablets delivering a standardized dose of domperidone 10mg. The product is supplied in multiple pack sizes ranging from 100 to 500 tablets, catering to individual and bulk purchasing needs. This formulation is intended for oral administration and should be stored at controlled room temperature away from moisture and direct sunlight. Clinicians often consider it when patients experience difficulty with gastrointestinal motility or when nausea is associated with gastrointestinal reflux or postoperative recovery. The tablet’s dispersible design allows it to be taken with or without water, facilitating administration for patients who have difficulty swallowing whole tablets.

What is Vomistop Tablet

Vomistop Tablet contains the active ingredient domperidone, a selective dopamine D2 receptor antagonist that enhances gastrointestinal motility by increasing the amplitude of gastric and intestinal contractions. The medication belongs to the class of prokinetic agents and is primarily indicated for the short‑term relief of nausea and vomiting in adults. It is not intended for use in pediatric populations unless specifically prescribed by a qualified healthcare professional. The tablet is classified under the gastrointestinal category and is marketed under the brand name Vomistop by Cipla Limited, a reputable pharmaceutical manufacturer with a global presence in the production of high‑quality generic medicines.

Uses and Benefits

The therapeutic uses of Vomistop Tablet extend to the management of nausea and vomiting associated with various clinical conditions such as gastroparesis, chemotherapy‑induced nausea, and postoperative nausea. Patients often report a reduction in the frequency and intensity of nausea episodes, allowing for improved nutrient intake and comfort. The medication may also be used to accelerate gastric emptying in individuals with delayed gastric motility, thereby decreasing the duration of symptoms. In addition to its primary indication, Vomistop may be prescribed off‑label for certain endocrine disorders that affect gastrointestinal function, provided that a physician evaluates the risk‑benefit profile. The benefits of using Vomistop include rapid onset of action, a well‑characterized safety profile when used as directed, and the convenience of a once‑daily or multiple‑times‑daily dosing schedule depending on the clinical scenario. For detailed regulatory information, see the U.S. Food and Drug Administration and National Institutes of Health.

How It Works

Domperidone present in Vomistop Tablet exerts its pharmacological effect by blocking dopamine receptors located in the chemoreceptor trigger zone of the brain and in the gastrointestinal tract. This antagonism reduces the signals that initiate the vomiting reflex, while simultaneously enhancing the coordinated contractions of the stomach and intestines, which promotes more efficient food passage. The drug does not cross the blood‑brain barrier to a significant extent, which minimizes central nervous system side effects compared to other dopamine antagonists. Pharmacokinetic studies indicate that the medication reaches peak plasma concentrations within approximately one hour after ingestion, and its therapeutic effect can persist for several hours, supporting multiple dosing throughout the day when necessary. The dispersible formulation ensures uniform distribution of the active ingredient, facilitating consistent absorption and predictable clinical response.

Dosage Guidelines

Patients are advised to follow the dosing instructions provided by their prescribing clinician or as outlined in the patient information leaflet. In general, the recommended regimen for adults involves taking one tablet up to four times daily before meals and at bedtime, depending on the severity of symptoms. The total daily dose should not exceed the limit specified by the treating physician, and the medication should not be used for more than a short defined period without medical review. It is important to swallow the tablet whole with sufficient water unless a dispersible form is specifically indicated, in which case it may be dissolved in a small amount of liquid. Missed doses should be skipped rather than doubled, and patients should avoid taking the medication more frequently than prescribed. Individuals with hepatic impairment or those taking concomitant medications that affect cardiac conduction should consult their healthcare provider before initiating therapy. For comprehensive safety data, consult MedlinePlus.

Side Effects

Like all pharmaceutical products, Vomistop Tablet may be associated with adverse effects, although not every user will experience them. Commonly reported side effects include dry mouth, headache, and mild abdominal discomfort. Less frequent but clinically significant reactions can involve cardiac arrhythmias, particularly in patients with pre‑existing electrolyte disturbances or those taking other QT‑prolonging agents. Neurological symptoms such as extrapyramidal disorders are rare but have been documented in post‑marketing surveillance. Common side effect profiles are also documented on Drugs.com. Patients should discontinue use and seek immediate medical attention if they develop severe dizziness, palpitations, or signs of an allergic reaction such as rash, swelling, or difficulty breathing. Routine monitoring of cardiovascular parameters is recommended for individuals with a history of heart disease.

Warnings and Precautions

Before initiating treatment with Vomistop Tablet, healthcare professionals should assess the patient’s cardiac history, electrolyte levels, and concomitant medication profile. The drug is contraindicated in individuals with known hypersensitivity to domperidone or any of the excipients, as well as in patients with a history of prolonged QT interval or recent myocardial infarction. Caution is advised in pregnant or breastfeeding women, as the safety of prolonged use in these populations has not been fully established. Additionally, the medication should be used with care in patients with hepatic or renal impairment, as metabolic clearance may be reduced, increasing the risk of accumulation. It is essential to store the tablets in a dry place, away from direct heat, and to keep them out of reach of children. Finally, patients should be instructed not to share the medication with others, even if they present with similar symptoms, to avoid inappropriate use.

Frequently Asked Questions

Q: What condition does Vomistop Tablet treat?
A: Vomistop Tablet is indicated for the relief of nausea and vomiting in adults, particularly when these symptoms are related to gastrointestinal motility disorders or chemotherapy.

Q: Is Vomistop available over the counter?
A: No, Vomistop Tablet is a prescription medication and should be obtained only with a valid prescription from a licensed healthcare provider.

Q: How quickly does the medication start working?
A: The onset of action typically occurs within one hour after ingestion, providing relatively rapid symptom relief for many patients.

Q: Can Vomistop be taken with other gastrointestinal drugs?
A: It may be used in combination with certain anti‑emetics or prokinetics, but potential drug interactions should be reviewed by a clinician before concurrent use.

Q: What should I do if I miss a dose?
A: If a dose is missed, it should be skipped and the regular dosing schedule resumed; doubling the dose is not recommended.

Related Products

• Ciplox 750mg (Ciprofloxacin)
• Diclofenac SR 100 mg
• Reactin 50 mg (Diclofenac)
• Cromal Forte Eye Drop (Sodium Cromoglycate)
• Alendronic Acid 35 mg (Generic)
• Rizact 5 mg (Rizatriptan)
• Flunarizine 5 mg (Generic)
• Warf 1 mg (Warfarin)
• Warf 2 mg (Warfarin)
• Warf 3 mg (Warfarin)
• Mucinac 200 mg (Acetylcysteine)
• Temozolomide 20 mg (Generic)